GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeutics due to their pleiotropic effects beyond glycemic control. Mechanistically, GLP-1 signaling modulates immune and inflammatory pathways, regulates autophagy and pyroptosis, alleviates endoplasmic reticulum stress, and interacts with the gut microbiome. These pleiotropic effects provide a rationale for exploring their role in multiple organ systems. Clinical trials have demonstrated cardiovascular and renal protection, leading to additional approvals in high-risk populations. Early data also suggest potential benefits in liver disease, obstructive sleep apnea, chronic respiratory disorders, neurodegenerative and psychiatric conditions, reproductive dysfunction, obesity-associated cancers, and sepsis, although these remain investigational. Therefore, this review aims to synthesize the evidence on the mechanistic expansion of GLP-1RAs from metabolic regulators to systemic modulators of inflammation, autophagy, and organ protection, and explores their therapeutic repurposing across diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our results show pleiotropic anti-inflammatory and antioxidant effects that may mechanistically underlie the cardiovascular, hepatic, and renal protection consistently seen in large-scale cardiovascular outcome studies (45, 46), in addition to their well-established benefits on glycemic control and weight reduction (47, 48).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“…signi fi cantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023; Marso et al., 2016a).”
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638 · cited 1×
“For example, following the induction of intestinal ischemia in humans, a rapid increase in GLP-1 secretion was observed, suggesting a link between endogenous LPS translocation and GLP-1 activation under conditions of barrier dysfunction (Cani et al., 2007; Lebrun et al., 2017).”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“…signi fi cantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023; Marso et al., 2016a).”
Biological Functions of Autophagy Genes: A Disease Perspective
Levine, B., & Kroemer, G. (2019) · Cell · doi:10.1016/j.cell.2018.09.048 · Cited by 2,832
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“…short-duration agents like exenatide, to intermediate-duration formulations such as liraglutide, and further to advanced long-acting options including dulaglutide and semaglutide (The two products received approval for marketing in the U.S. in 2014 and 2017, respectively) (Pfeffer et al., 2015).”
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964 · cited 1×
“Exenatide, the fi rst GLP-1RA approved in 2005, demonstrated clinical ef fi cacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021).”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Since the discovery and functional veri fi cation of GLP-1 in the 1980s (Kreymann et al., 1987), it has markedly reshaped current clinical approaches to the treatment of obesity and type 2 diabetes, providing superior glycemic control with reduced hypoglycemic risks compared to conventional…”
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Gut microbial metabolites in obesity, NAFLD and T2DM
Canfora, E. E., Meex, R. C. R., Venema, K., & Blaak, E. E. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0156-z · Cited by 1,493 · cited 1×
“Study found that increasing endogenous and exogenous intestinal SCFAs can stimulate intestinal endocrine cells to secrete GLP-1 and PYY by binding to GPR41 and GPR43 (Canfora et al., 2019).”
The cancer metabolic reprogramming and immune response
Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., Yi, P., Tang, L., Pan, Q., Rao, S., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01316-8 · Cited by 1,312 · cited 1×
“…and transform their metabolic patterns to adapt to changes in the external environment and to meet their own needs for growth and differentiation, by engaging various bioenergetic routes, such as glucose utilization, lipid metabolism, and amino acid metabolism (Xia et al., 2021; Yang et al., 2023).”
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 2×
“These include facilitating glucose reduction, delaying gastric motility, improving insulin responsiveness, and inhibiting glucagon production (Meier, 2012).”
Sepsis: pathophysiology and clinical management
Gotts, J. E., & Matthay, M. A. (2016) · BMJ · doi:10.1136/bmj.i1585 · Cited by 1,243 · cited 1×
“It remains a leading cause of mortality and morbidity in intensive care units (ICUs) worldwide (Gotts and Matthay, 2016).”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Psichas, A., Sleeth, M. L., Murphy, K. G., Brooks, L., Bewick, G. A., Hanyaloglu, A. C., Ghatei, M. A., Bloom, S. R., & Frost, G. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.153 · Cited by 886
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871 · cited 2×
“In 2024, tirzepatide also gained authorization for managing moderate-to-severe obstructive sleep apnea (OSA) in obese adults (Malhotra et al., 2024).”
InfluentialMacrophage Polarization in Physiological and Pathological Pregnancy
Yao, Y., Xu, X.-H., & Jin, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00792 · Cited by 825 · cited 1×
“Macrophages can polarize into two distinct phenotypes: M1, which exhibits pro-in fl ammatory properties, and M2, which is associated with anti-in fl ammatory functions (Zhang et al., 2023; Yao et al., 2019).”
Guo, S., Al-Sadi, R., Said, H. M., & Ma, T. Y. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.10.014 · Cited by 719
Yoon, H. S., Cho, C. H., Yun, M. S., Jang, S. J., You, H. J., Kim, J.-H., Han, D., Cha, K. H., Moon, S. H., Lee, K., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00880-5 · Cited by 602
Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells
Chimerel, C., Emery, E., Summers, D. K., Keyser, U., Gribble, F. M., & Reimann, F. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.032 · Cited by 548
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 2×
“Kim et al. (2013) fi rst identi fi ed that GLP-1 receptor agonists (GLP-1RAs) enhance renal perfusion, a mechanism mediated by increased atrial natriuretic peptide (ANP) secretion.”
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383 · cited 1×
“Liraglutide and dulaglutide generally show better tolerability but still require careful counseling to maintain adherence (Drucker, 2024).”
Microbial Modulation of Energy Availability in the Colon Regulates Intestinal Transit
Wichmann, A., Allahyar, A., Greiner, T. U., Plovier, H., Lundén, G. Ö., Larsson, T., Drucker, D. J., Delzenne, N. M., Cani, P. D., & Bäckhed, F. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.09.012 · Cited by 380
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300 · cited 1×
“In the U.S. Department of Veterans Affairs database found that GLP-1RA therapy reduced the risk of dementia and AD by 8% and 12%, respectively (Xie et al., 2025).”
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.013 · Cited by 281
The role of lipid metabolic reprogramming in tumor microenvironment
Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023) · Theranostics · doi:10.7150/thno.82920 · Cited by 270
Sun, J., Li, H., Jin, Y., Yu, J., Mao, S., Su, K.-P., Ling, Z., & Liu, J. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.014 · Cited by 264
Liu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253 · cited 1×
“It originates from the post-translational modi fi cation of the proglucagon precursor and exerts diverse metabolic functions via binding to the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR) that is extensively distributed among numerous organ systems (Aroda, 2018).”
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., et al. (2017) · Nature · doi:10.1038/nature22378 · Cited by 241 · cited 1×
“Moreover, GLP-1R expression has also been detected in several components of the immune system, such as macrophages, lymphocytes, and invariant natural killer T (iNKT) cells (Song et al., 2017).”
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238 · cited 2×
“For example, following the induction of intestinal ischemia in humans, a rapid increase in GLP-1 secretion was observed, suggesting a link between endogenous LPS translocation and GLP-1 activation under conditions of barrier dysfunction (Cani et al., 2007; Lebrun et al., 2017).”
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Kahles, F., Meyer, C., Möllmann, J., Diebold, S., Findeisen, H. M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., et al. (2014) · Diabetes · doi:10.2337/db14-0100 · Cited by 212
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207
Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy
Yang, H., & Yang, L. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0316 · Cited by 203
Yu, X., Hao, M., Liu, Y., Ma, X., Lin, W., Xu, Q., Zhou, H., Shao, N., & Kuang, H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172715 · Cited by 190
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.010 · Cited by 185 · cited 1×
“Furthermore, real-world data from Epic Research suggested that users of tirzepatide, semaglutide, dulaglutide, or exenatide had a lower risk of depression than non-users, although this study is pending peer review (Chen et al., 2024).”
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Kaji, I., Karaki, S.-I., Tanaka, R., & Kuwahara, A. (2010) · Journal of Molecular Histology · doi:10.1007/s10735-010-9304-4 · Cited by 166
Wang, L., Li, P., Tang, Z., Yan, X., & Feng, B. (2016) · Scientific Reports · doi:10.1038/srep33251 · Cited by 165
Zhao, L., Chen, Y., Xia, F., Abudukerimu, B., Zhang, W., Guo, Y., Wang, N., & Lu, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00233 · Cited by 165
Nguyen, A. T., Mandard, S., Dray, C., Deckert, V., Valet, P., Besnard, P., Drucker, D. J., Lagrost, L., & Grober, J. (2014) · Diabetes · doi:10.2337/db13-0903 · Cited by 161
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160
Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100679 · Cited by 155
Zummo, F. P., Cullen, K. S., Honkanen‐Scott, M., Shaw, J., Lovat, P. E., & Arden, C. (2017) · Diabetes · doi:10.2337/db16-1009 · Cited by 148
Gut microbiota regulates postprandial GLP-1 response via ileal bile acid-TGR5 signaling
Wang, Q., Lin, H., Shen, C., Zhang, M., Wang, X., Yuan, M., Yuan, M., Jia, S., Cao, Z., Wu, C., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2274124 · Cited by 140
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Microbial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 131 · cited 1×
“Microbial metabolites — postbiotics — also serve as potent regulators of GLP-1 signaling (Greiner and Backhed, 2016).”
Qi, Q., Zhang, H., Jin, Z., Wang, C., Xia, M., Chen, B., Lv, B., Diaz, L. P., Li, X., Feng, R., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01068-x · Cited by 130
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126
Madsen, M. S. A., Holm, J. B., Pallejà, A., Wismann, P., Fabricius, K., Rigbolt, K., Mikkelsen, M., Sommer, M., Jelsing, J., Nielsen, H. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52103-x · Cited by 121
Steven, S., Jurk, K., Kopp, M., Kröller‐Schön, S., Mikhed, Y., Schwierczek, K., Roohani, S., Kashani, F., Oelze, M. W., Klein, T., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13549 · Cited by 117
Yun, C., Yan, S., Liao, B., Ding, Y., Qi, X., Zhao, M., Wang, K., Zhuo, Y., Nie, Q., Ye, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01041-8 · Cited by 110 · cited 1×
“Interestingly, agmatine, a metabolite produced by the gut bacterium Bacteroides vulgatus — was shown to impair ovarian function by inhibiting GLP-1 secretion through activation of the farnesoid X receptor (FXR) (Yun et al., 2024).”
Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial
Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504214 · Cited by 110
Cai, X., She, M., Xu, M., Chen, H., Li, J., Chen, X., Zheng, D., Liu, J., Chen, S., Zhu, J., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27774 · Cited by 109
Song, S., Guo, R., Mehmood, A., Zhang, L., Yin, B., Yuan, C., Zhang, H., Guo, L., & Li, B. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13791 · Cited by 109
Chen, A., Chen, Z., Xia, Y., Lu, D., Yang, X., Sun, A., Zou, Y., Qian, J., & Ge, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.142 · Cited by 108
Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats
Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., Wang, T., & Wang, X. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217743765 · Cited by 101 · cited 4×
“…↑ Firmicutes , Bacteroidetes , Actinomycetes ↓ Proteobacteria ↑ Escherichia coli (restructuring effect) ↑ Alistipes (not statistically signi fi cant) Zhang et al., 2018; Zhao et al., 2018; Shang et al., 2021; Yi et al., 2024; Liu et al., 2020; Ying et al., 2023; Kim et al., 2022; Kato et al., 2021;…”
InfluentialLiraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
Liu, Q., Cai, B.-Y., Zhu, L., Xin, X., Wang, X., An, Z., Li, S., Hu, Y., & Feng, Q. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118457 · Cited by 100
Outeiriño-Iglesias, V., Romaní-Pérez, M., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1978 · Cited by 99
Yao, R.-Q., Ren, C., Wang, J., Wu, G., Zhu, X., Xia, Z., & Yao, Y.-M. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.37496 · Cited by 95
A newly identified protein from Akkermansia muciniphila stimulates GLP-1 secretion
Cani, P. D., & Knauf, C. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.05.004 · Cited by 94
de Paiva, I. H. R., da Silva, R. S., Mendonça, I. P., Maciel, L. M., de Souza, J. R. B., & Peixoto, C. A. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10142-w · Cited by 93
Metabolic reprogramming in skeletal cell differentiation
Bertels, J., He, G., & Long, F. (2024) · Bone Research · doi:10.1038/s41413-024-00374-0 · Cited by 92 · cited 1×
“Its diversity and vulnerability make the involved pathway proteins potential therapeutic targets (Horn and Tacke, 2024; Bertels et al., 2024).”
Giorgi, R. D., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 92
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress
Jiang, Y., Wang, Z., Ma, B., Fan, L., Yi, N., Lu, B., Wang, Q., & Liu, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01168 · Cited by 88
Shang, J., Liu, F., Zhang, B., Dong, K., Lu, M., Jiang, R., Xu, Y., Diao, L., Zhao, J., & Tang, H. D. (2021) · PeerJ · doi:10.7717/peerj.11128 · Cited by 82
A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome
Kim, E. R., Park, J. S., Kim, J. H., Oh, J. Y., Oh, I. J., Choi, D. H., Lee, Y. S., Park, I. S., Kim, S., Lee, D. H., et al. (2021) · Hepatology · doi:10.1002/hep.32235 · Cited by 82
Chen, J., Hsu, T., Liu, J.-H., Pan, H., Lai, C., Yang, S., & Wu, V. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.013 · Cited by 81
Kaihara, K. A., Dickson, L. M., Jacobson, D. A., Tamarina, N., Roe, M. W., Philipson, L. H., & Wicksteed, B. (2013) · Diabetes · doi:10.2337/db12-1013 · Cited by 80
Smits, M. M., Fluitman, K. S., Herrema, H., Davids, M., Kramer, M. H. H., Groen, A. K., Belzer, C., de Vos, W. M., Cahen, D. L., Nieuwdorp, M., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101223 · Cited by 75
Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165722 · Cited by 69
Tian, S., Lei, Y., Zhao, F., Che, J., Wu, Y.-H., Lei, P., Kang, Y. E., & Shan, Y. (2024) · Food & Function · doi:10.1039/d4fo01059k · Cited by 67 · cited 1×
“Additional fi ndings highlight that dietary compounds like sulforaphane (SFN) may potentiate SCFA signaling to augment GLP-1 release while concurrently attenuating intestinal in fl ammation (Tian et al., 2024).”
Helmstädter, J., Keppeler, K., Aust, F., Küster, L., Frenis, K., Filippou, K. V., Vujačić-Mirski, K., Tsohataridis, S., Kalinovic, S., Kröller‐Schön, S., et al. (2021) · Antioxidants · doi:10.3390/antiox10081175 · Cited by 66
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet
Duan, X., Zhang, L., Liao, Y., Lin, Z., Guo, C., Luo, S., Wang, F., Zou, Z., Zeng, Z., Chen, C., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176440 · Cited by 66
Self-citationGLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Lebherz, C., Schlieper, G., Möllmann, J., Kahles, F., Schwarz, M., Brünsing, J., Dimkovic, N., Koch, A., Trautwein, C., Flöge, J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.010 · Cited by 65
Zhou, M., Mok, M. T. S., Sun, H., Chan, A. W. H., Huang, Y., Cheng, A. S. L., & Xu, G. (2017) · Oncogene · doi:10.1038/onc.2017.38 · Cited by 63 · cited 1×
“Exendin-4 treatment rescued lysosomal activity, normalized autophagic clearance, and enhanced autophagic fl ux, thus preserving β -cell viability (Zummo et al., 2017).”
Cheng, C. K., Luo, J., Lau, C. W., Cho, W. C. S., Ng, C., Ronald, C. W., Tian, X. Y., & Huang, Y. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00589-x · Cited by 61 · cited 1×
“In vascular dysfunction, Exendin-4 attenuates hyperhomocysteinemia (HHcy)-induced endothelial ER stress via AMPK-dependent upregulation of ERO1 α , restoring vascular function (Sawada et al., 2020; Cheng et al., 2021).”
Sanchez-Garrido, M. A., Serrano-López, V., Ruíz-Pino, F., Vazquez, M. J., Rodríguez-Martín, A., Torres, E., Velasco, I., Rodríguez, A., Chicano‐Gálvez, E., Mora-Ortiz, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52898-y · Cited by 60
Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-88612-x · Cited by 59 · cited 2×
“…et al. demonstrated that liraglutide modulates the composition of obesity-associated gut microbiota, such as Escherichia coli , markedly restructuring the microbial community and reshaping bacterial taxa linked to body weight regulation, thereby contributing to weight reduction (Kato et al., 2021).”
Tao, X., Cai, L., Chen, L., Ge, S., & Deng, X. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0555-8 · Cited by 58
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
Wang, W., Mei, A., Qian, H., Li, D., Xu, H., Chen, J., Yang, H., Min, X., Li, C., Li, C., et al. (2023) · International Journal of COPD · doi:10.2147/copd.s393323 · Cited by 58
Self-citationWan, S., & Sun, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7347 · Cited by 55
Sun, H., Shu, J., Tang, J., Li, Y., Qiu, J., Ding, Z., Xuan, B., Chen, M., Gan, C., Lin, J., et al. (2024) · Immunology · doi:10.1111/imm.13784 · Cited by 54
Wang, L., Wang, Q., Li, L., Kaelber, D. C., & Xu, R. (2025) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djae260 · Cited by 53
Impact of GLP-1 Agonists on Male Reproductive Health—A Narrative Review
Varnum, A. A., Pozzi, E., Deebel, N. A., Evans, A., Eid, N., Sadeghi‐Nejad, H., & Ramasamy, R. (2023) · Medicina · doi:10.3390/medicina60010050 · Cited by 51
Jiang, Y., Yang, J., Li, X., Wei, T., Cui, X., Wang, D., Jin, Z., Lin, X., Li, F., Yang, K., et al. (2024) · Diabetes · doi:10.2337/db23-0553 · Cited by 51
Havranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 51
Guo, H., Guo, Q., Li, Z., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1461398 · Cited by 49 · cited 1×
“Other safety considerations include rare reports of pancreatitis and the unresolved concern regarding thyroid C-cell tumors, as re fl ected by boxed warnings (Espinosa et al., 2024; Guo et al., 2024).”
Yao, M., Zhang, J., Zhi-hong, L., Bai, X., Ma, J., & Li, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.630962 · Cited by 47
Ying, X., Rongjiong, Z., Kahaer, M., Chunhui, J., & Wulasihan, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1088187 · Cited by 47
Brakenridge, S. C., Moore, F. A., Mercier, N. R., Cox, M., Wu, Q., Moldawer, L. L., Mohr, A. M., Efron, P. A., & Smith, S. R. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.04.014 · Cited by 46
GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
Ku, H.-C., Chen, W., & Su, M. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0559-9 · Cited by 45
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01118-6 · Cited by 44
Yang, C., Yao, W., Yang, C., Peng, Z., Ou, H., & Kuo, S. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13751 · Cited by 42
Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease
Tomaro-Duchesneau, C., LeValley, S. L., Roeth, D., Sun, L. T., Horrigan, F. T., Kalkum, M., Hyser, J. M., & Britton, R. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61112-0 · Cited by 40
Yi, H., Duan, Y., Song, R., Zhou, Y., Cui, Y., Liu, C., Mao, Z., Hu, J., & Zhou, F. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114348 · Cited by 40
The gut microbiota modulate locomotion via vagus-dependent glucagon-like peptide-1 signaling
Lai, T.-T., Tsai, Y.-H., Liou, C.-W., Fan, C., Hou, Y.-T., Yao, T.-H., Chuang, H.-L., & Wu, W. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00477-w · Cited by 40
da Silva, R. S., de Paiva, I. H. R., Mendonça, I. P., de Souza, J. R. B., Lucena‐Silva, N., & Peixoto, C. A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01603-y · Cited by 39
Fredborg, M., Theil, P. K., Jensen, B. B., & Purup, S. (2012) · Journal of Animal Science · doi:10.2527/jas.53792 · Cited by 38
Leonardini, A., D’Oria, R., Incalza, M. A., Caccioppoli, C., Buccheri, V. A., Cignarelli, A., Paparella, D., Margari, V., Natalicchio, A., Perrini, S., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00970 · Cited by 38
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
Sawada, N., Adachi, K., Nakamura, N., Miyabe, M., Ito, M., Kobayashi, S., Miyajima, S., Suzuki, Y., Kikuchi, T., Mizutani, M., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8843310 · Cited by 37
Ma, B., Wang, X., Ren, H., Li, Y., Zhang, H., Yang, M., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11077-w · Cited by 36
Zhang, Y., Tang, C., He, Y., Zhang, Y., Li, Q., Zhang, T., Zhao, B., Tong, A., Zhong, Q., & Zhong, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117540 · Cited by 36
Zeng, S.-S., Bai, J.-J., Jiang, H., Zhu, J.-J., Fu, C.-C., He, M.-Z., Zhu, J.-H., Chen, S.-Q., Li, P.-J., Fu, X.-Q., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00585 · Cited by 35
Sepsis‐induced activation of endogenous GLP‐1 system is enhanced in type 2 diabetes
Perl, S. H., Bloch, O., Zelnic‐Yuval, D., Love, I., Mendel‐Cohen, L., Flor, H., & Rapoport, M. J. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2982 · Cited by 34 · cited 1×
“On the contrary, increased GLP-1 levels are more likely to represent an adaptive, protective response to systemic stress and in fl ammation (Perl et al., 2018; Lebherz et al., 2017).”
Liu, J., Wei, L., Wang, Z., Song, S., Lin, Z., Zhu, J., Ren, X. S., & Kong, L. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104624 · Cited by 33
Yin, W., Jiang, Y., Xu, S., Wang, Z., Peng, L., Fang, Q., Deng, T., Zhao, W., Zhang, W., & Lou, J. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12956 · Cited by 32 · cited 1×
“In STZ-induced diabetic rats, Yin et al. (2019) further demonstrated that recombinant human GLP-1 (rhGLP-1) suppresses epithelial apoptosis and mitigates tubulointerstitial fi brosis via the PKA/PKC signaling pathway (Yin et al., 2019).”
Xu, X. J., Fukui, H., Ran, Y., Tomita, T., Oshima, T., Watari, J., & Miwa, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40978-9 · Cited by 29 · cited 1×
“These microbial changes signi fi cantly enhance GLP-1 activity (Xu et al., 2019).”
Sedky, A. A., & Magdy, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119523 · Cited by 29
Kassem, S., Khalaila, B., Stein, N., Saliba, W., & Zaina, A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15828 · Cited by 28
Beccuti, G., Bioletto, F., Parasiliti‐Caprino, M., Benso, A. S., Ghigo, E., Cicolin, A., & Broglio, F. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00592-x · Cited by 28
LeValley, S. L., Tomaro-Duchesneau, C., & Britton, R. A. (2020) · mSphere · doi:10.1128/msphere.00585-19 · Cited by 27 · cited 1×
“In addition, E. faecalis supernatants were capable of disrupting the colonic epithelial monolayer and cleaving GLP-1 in a gelE-dependent manner (Levalley et al., 2020).”
Singh, A., Fernandes, J. R. D., Chhabra, G., Krishna, A., & Banerjee, A. (2019) · Endocrine · doi:10.1007/s12020-019-01891-3 · Cited by 26
Valdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
Gao, Y., Ryu, H., Lee, H.-J., Kim, Y., Lee, J., & Lee, J. (2023) · Molecules and Cells · doi:10.1016/j.mocell.2023.12.002 · Cited by 23
Rizza, S., Pietrucci, D., Longo, S., Menghini, R., Teofani, A., Piciucchi, G., Montagna, M., & Federici, M. (2023) · PubMed Central · doi:10.14336/ad.2023.0118 · Cited by 17
Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline
Yi, B., Su, K., Cai, Y., Chen, X., Bao, Y., & Wen, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176905 · Cited by 12
Wiberg, S. C., Kjærgaard, J., Schmidt, H., Thomsen, J. H., Frydland, M. S., Winther‐Jensen, M., Lindholm, M. G., Høfsten, D. E., Engstrøm, T., Køber, L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002814 · Cited by 11
Zhang, X., Yang, X., Zhang, S., Wang, J., Wang, M., Ma, T., Wan, M., Lv, X., Yan, T., & Jia, Y. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad014 · Cited by 10
GLP1: the early steps of a success story
Bakar, R. B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00821-8 · Cited by 7 · cited 1×
“Glucagon-like peptide-1 (GLP-1) belongs to a class of intestinally derived hormones known as incretins (Bany Bakar, 2023).”
Cited by
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031186 · Cited by 11
“Treatment with semaglutide has been associated with preferential reductions in visceral adipose tissue mass, improvements in body fat distribution, and decreases in circulating lipid intermediates linked to insulin resistance [30,31].”
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1734549 · Cited by 4
Iwasaki, Y., Shimada, T., Kishimori, T., Kato, T., Koike, J., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113072 · Cited by 2
Metadata
- Authors
- Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H.
- Affiliations
- Kunming University of Science and Technology (CN)
- Corresponding author
- Chen, Guobing
- Su, Heng
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2025-09-11
- Volume
- 16
- Pages
- 1675552-1675552
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC12461214
- OpenAlex
- W4414131365
- Cited by
- 36
- References
- 141
- Citations by year
- 2026: 33 · 2025: 3
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, pleiotropy, inflammation, autophagy, pyroptosis, endoplasmic reticulum stress, gut microbiota, cardioprotection, renal protection, liver disease, obstructive sleep apnea, neurodegenerative diseases, mental illness, reproductive disorders, obesity-related cancer, sepsis, drug repurposing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.